Columns

Even the cold and rainy Southern California weather did little to dampen the excitement of the more than 1,800 attendees converging on the Marriott Marquis San Diego Marina. People filtered in, eager for the meeting to begin. Excitement reached a fever pitch Thursday morning as the curriculum came to life.

Want to reduce your multiple sclerosis (MS) fatigue? Maybe we should talk about it. I’m talking about a fatigue treatment called cognitive behavioral therapy (CBT), which usually involves changing a person’s thinking and behavior. By talking with a therapist, sometimes on the phone, a patient develops an…

Every once in a while, I wake up prepared to swing my legs over the side of the bed and get moving. That sleep-induced forgetfulness evaporates as soon as the reality of multiple sclerosis (MS) reminds me that I can’t swing anything. I suppose I should be grateful that…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. In this column, I’ll be highlighting some MS News Today stories from last week’s Americas Committee for Treatment and Research in Multiple Sclerosis…

If you have multiple sclerosis (MS), I’m sure you’ve had several MRIs by now. You’ve probably also had one using a contrast agent. The contrast agent is made from a rare earth element called gadolinium. Mixed with other chemical ions, it highlights lesions or areas…

We had family portraits made a few days ago. With a family of five, this never goes perfectly, so there was a little pre-photo briefing beforehand. There were some veiled threats, a promise of dinner after as a reward for good behavior, and more than a few hissed admonishments to…

It’s been a couple weeks since my last column, and things with my mother have proven more challenging than we expected. She’s had another minor procedure to stop fluid from building up in her chest, but she is progressing with her rehab and continues to gain strength. Hopefully, we’ll…

Welcome to “MS News Notes,” a Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: More remyelination research For years, most MS research has focused on stopping disease progression. In the past couple…

It was bound to happen. Even though it’s been more than three years since COVID-19 reared it head in Wuhan, China, and even though I’ve had five of the COVID-19 vaccine shots recommended by the U.S. Centers for Disease Control and Prevention — two primary series doses and three…

I am not by nature a very neat person. I want to be. I like order, but I lack the discipline to maintain it. People tend to think that time in the military makes you neat and orderly for the rest of your life, but in my case, they’d be…

Welcome to “MS News Notes,” a weekly Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Older patients and DMTs The title of a report by MS News Today‘s Patricia Inacio notes…

Note: This column has been updated Feb. 15, 2023, to correct that Ocrevus is an infusion medication and is not similar to chemotherapy. Is treating multiple sclerosis (MS) really all about the medications? At least one neurologist thinks so, probably more, and I think that’s no way to practice…

“scabulous adj. proud of a scar on your body, which is an autograph signed to you by a world grateful for your continued willingness to play with her, even when you don’t feel like it.” — John Koenig, “The Dictionary of Obscure Sorrows“ I’ve managed to amass quite the…

Well, dear readers, I took a bit of time off from writing this column, but not by choice. January was an incredibly hectic 31 days, and I spent most of them living with my parents in Florida. Why? Well, because my mother has been dealing with some health issues…

Welcome to “MS News Notes,” a weekly Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Tysabri biosimilar on the horizon Tysabri (natalizumab) is a very effective disease-modifying therapy (DMT) for…

Have you ever heard of an ABLE savings account? I hadn’t until a couple weeks ago. The acronym stands for the Achieving a Better Life Experience Act, a law passed by the U.S. Congress in 2014. It created special savings accounts that allow disabled Americans, including people with…

Summer is one of the cruelest times of year for people with multiple sclerosis (MS). Thanks to Uhthoff’s syndrome, it’s hard to enjoy all the fun that comes with warm temperatures. I don’t seem to sweat anymore (not that it helps much in our high humidity), so I…

Welcome to “MS News Notes,” a weekly Monday morning column where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: A protein to restore myelin? I usually don’t like to comment on stories about mouse studies, because…

A recent question on the MS News Today Facebook page generated some buzz about getting a buzz on to treat your multiple sclerosis (MS). The question was, “What helps you the most to manage your daily life with MS?” Many people with MS said the thing that helped…

The other day, my middle child opened the door while I was in the bathroom. If you have children, a surprise visit in what should be a sanctuary isn’t unusual, but in this case, what he said was. He observed me aboard my toilet and shower chair, which progressive…

“You only begin to grasp the import of an event – and its larger implications vis-à-vis your life – long after it has entered into that realm marked ‘memory.’” — Douglas Kennedy, “The Moment“ I am reading my first book since multiple sclerosis (MS) fatigue reared its…

Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Gilenya alternative The disease-modifying therapy (DMT) Gilenya (fingolimod) has been around since 2010. Now the U.S. Food and Drug Administration has…

As you read this, a group of scientists is doing multiple sclerosis (MS) research high above the earth. Their laboratory is in orbit about 250 miles up, aboard the International Space Station. Working with researchers at the New York Stem Cell Foundation (NYSCF), astronauts have been helping…

Before multiple sclerosis (MS), I was pretty proud of my memory. For the most part, I still am, but like many others with this disease, I now have trouble recalling information. For me, it’s one of the most irritating, (sometimes even infuriating), cognitive issues associated with MS. I…

Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Could COVID-19 trigger MS? Since the start of the COVID-19 pandemic, there have been scattered reports of people who’ve developed neurological disorders,…

“I was told I’m in a flare-up,” a newly diagnosed person with multiple sclerosis (MS) wrote to a Facebook group the other day. She said the flare-up had been going on “for a while now” and wondered when she could expect it to calm down. After I pondered…

“The secret of change is to focus all of your energy, not on fighting the old, but on building the new.” — Dan Millman I’m now living with multiple chronic illnesses. Lately, time has been rushing past like a ravenous flood, or standing still like a lonesome statue. In…

One of my favorite episodes of “I Love Lucy” is the one where Lucy and Ethel get up to some hijinks (and don’t they always?) in a candy factory. You know the one. At first, the bonbons come down the belt slowly, each one easy to wrap. But…

Welcome to “MS News Notes,” where I comment on multiple sclerosis (MS) news stories that caught my eye last week. Here’s a look at what’s been happening: Tongue stimulator now easier to obtain A Portable Neuromodulation Stimulator (PoNS) is a mouthpiece that mildly stimulates nerves in the tongue that…

The new year is bringing a new disease-modifying therapy (DMT) to the multiple sclerosis (MS) arsenal. Shortly after Christmas, the U.S. Food and Drug Administration (FDA) approved Briumvi (ublituximab), which joins a small group of DMTs that aim to halt MS progression by knocking out certain…